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inTrOducTiOn
Nucleic acid sequencing is a method for determining 
the exact order of nucleotides present in a given DNA or 
RNA molecule. In the past decade, the use of nucleic acid 
sequencing has increased exponentially as the ability to 
sequence has become accessible to research and clini-
cal labs all over the world. The first major foray into DNA 
sequencing was the Human Genome Project, a $3 billion, 
13-year-long endeavor, completed in 2003. The Human 
Genome Project was accomplished with first-generation 
sequencing, known as Sanger sequencing. Sanger sequenc-
ing (the chain-termination method), developed in 1975 
by Edward Sanger, was considered the gold standard for 
nucleic acid sequencing for the subsequent two and a half 
decades (Sanger et al., 1977).
Since completion of the first human genome sequence, 
demand for cheaper and faster sequencing methods has 
increased greatly. This demand has driven the develop-
ment of second-generation sequencing methods, or next-
generation sequencing (NGS). NGS platforms perform 
massively parallel sequencing, during which millions of 
fragments of DNA from a single sample are sequenced in 
unison. Massively parallel sequencing technology facili-
tates high-throughput sequencing, which allows an entire 
genome to be sequenced in less than one day. In the past 
decade, several NGS platforms have been developed that 
provide low-cost, high-throughput sequencing. Here we 
highlight two of the most commonly used platforms in 
research and clinical labs today: the LifeTechnologies Ion 
Torrent Personal Genome Machine (PGM) and the Illumina 
MiSeq. The creation of these and other NGS platforms has 
made sequencing accessible to more labs, rapidly increas-
ing the amount of research and clinical diagnostics being 
performed with nucleic acid sequencing.
OVerVieW OF The meThOdOlOGY
Although each NGS platform is unique in how sequenc-
ing is accomplished, the Ion Torrent PGM and the Illumina 
MiSeq have a similar base methodology that includes tem-
plate preparation, sequencing and imaging, and data analysis 
(Metzker, 2010). Within each generalized step, the individual 
platforms discussed have unique aspects. An overview of the 
sequencing methodologies discussed is provided in Figure 1.
WHAT NGS DOES
•  NGS provides a much cheaper and higher-
throughput alternative to sequencing DNA than 
traditional Sanger sequencing. Whole small 
genomes can now be sequenced in a day.
•  High-throughput sequencing of the human 
genome facilitates the discovery of genes and 
regulatory elements associated with disease.
•  Targeted sequencing allows the identification 
of disease-causing mutations for diagnosis of 
pathological conditions.
•  RNA-seq can provide information on the entire 
transcriptome of a sample in a single analysis 
without requiring previous knowledge of the 
genetic sequence of an organism. This technique 
offers a strong alternative to the use of microarrays 
in gene expression studies.
LIMITATIONS 
•  NGS, although much less costly in time and money 
in comparison to first-generation sequencing, is 
still too expensive for many labs. NGS platforms 
can cost more than $100,000 in start-up costs, and 
individual sequencing reactions can cost upward of 
$1,000 per genome.
•  Inaccurate sequencing of homopolymer regions 
(spans of repeating nucleotides) on certain NGS 
platforms, including the Ion Torrent PGM, and 
short-sequencing read lengths (on average 200–500 
nucleotides) can lead to sequence errors.
•  Data analysis can be time-consuming and may 
require special knowledge of bioinformatics to 
garner accurate information from sequence data. 
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data analysis
Once sequencing is complete, raw sequence data must 
undergo several analysis steps. A generalized data analysis 
pipeline for NGS data includes preprocessing the data to 
remove adapter sequences and low-quality reads, mapping 
of the data to a reference genome or de novo alignment of 
the sequence reads, and analysis of the compiled sequence. 
Analysis of the sequence can include a wide variety of bio-
informatics assessments, including genetic variant calling for 
detection of SNPs or indels (i.e., the insertion or deletion of 
bases), detection of novel genes or regulatory elements, and 
assessment of transcript expression levels. Analysis can also 
include identification of both somatic and germline mutation 
events that may contribute to the diagnosis of a disease or 
genetic condition. Many free online tools and software pack-
ages exist to perform the bioinformatics necessary to success-
fully analyze sequence data (Gogol-Döring and Chen, 2012).
applicaTiOns
The applications of NGS seem almost endless, allowing for 
rapid advances in many fields related to the biological sci-
ences. Resequencing of the human genome is being per-
formed to identify genes and regulatory elements involved in 
pathological processes. NGS has also provided a wealth of 
knowledge for comparative biology studies through whole-
genome sequencing of a wide variety of organisms. NGS 
is applied in the fields of public health and epidemiology 
through the sequencing of bacterial and viral species to facili-
tate the identification of novel virulence factors. Additionally, 
gene expression studies using RNA-Seq (NGS of RNA) have 
begun to replace the use of microarray analysis, providing 
researchers and clinicians with the ability to visualize RNA 
expression in sequence form. These are simply some of the 
broad applications that begin to skim the surface of what 
NGS can offer the researcher and the clinician. As NGS con-
tinues to grow in popularity, it is inevitable that there will be 
additional innovative applications.
nGs in pracTice
Whole-exome sequencing
Mutation events that occur in gene-coding or control 
regions can give rise to indistinguishable clinical presenta-
tions, leaving the diagnosing clinician with many possible 
causes for a given condition or disease. With NGS, clini-
cians are provided a fast, affordable, and thorough way to 
determine the genetic cause of a disease. Although high-
throughput sequencing of the entire human genome is pos-
sible, researchers and clinicians are typically interested in 
only the protein-coding regions of the genome, referred to as 
the exome. The exome comprises just over 1% of the genome 
and is therefore much more cost-effective to sequence than 
the entire genome, while providing sequence information for 
protein-coding regions.
Exome sequencing has been used extensively in the past 
several years in gene discovery research. Several gene dis-
covery studies have resulted in the identification of genes 
that are relevant to inherited skin disease (Lai-Cheong and 
McGrath, 2011). Exome sequencing can also facilitate the 
Template preparation
Template preparation consists of building a library of nucleic 
acids (DNA or complementary DNA (cDNA)) and amplify-
ing that library. Sequencing libraries are constructed by frag-
menting the DNA (or cDNA) sample and ligating adapter 
sequences (synthetic oligonucleotides of a known sequence) 
onto the ends of the DNA fragments. Once constructed, 
libraries are clonally amplified in preparation for sequencing. 
The PGM utilizes emulsion PCR on the OneTouch system to 
amplify single library fragments onto microbeads, whereas 
the MiSeq utilizes bridge amplification to form template clus-
ters on a flow cell (Berglund et al., 2011; Quail et al., 2012).
sequencing and imaging
To obtain nucleic acid sequence from the amplified librar-
ies, the Ion Torrent PGM and the MiSeq both rely on 
sequencing by synthesis. The library fragments act as a 
template, off of which a new DNA fragment is synthesized. 
The sequencing occurs through a cycle of washing and 
flooding the fragments with the known nucleotides in a 
sequential order. As nucleotides incorporate into the grow-
ing DNA strand, they are digitally recorded as sequence. 
The PGM and the MiSeq each rely on a slightly different 
mechanism for detecting nucleotide sequence information. 
The PGM performs semiconductor sequencing that relies 
on the detection of pH changes induced by the release of 
a hydrogen ion upon the incorporation of a nucleotide into 
a growing strand of DNA (Quail et al., 2012). By contrast, 
the MiSeq relies on the detection of fluorescence generated 
by the incorporation of fluorescently labeled nucleotides 
into the growing strand of DNA (Quail et al., 2012).
Figure 1. next-generation sequencing methodology.
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identification of disease-causing mutations in pathogenic 
presentations where the exact genetic cause is not known.
Figure 2 (Cullinane et al., 2011) demonstrates the direct 
effect that NGS can have on the correct diagnoses of a 
patient. It summarizes the use of homozygosity mapping 
followed by whole-exome sequencing to identify two dis-
ease-causing mutations in a patient with oculocutaneous 
albinism and congenital neutropenia (Cullinane et al., 2011). 
Figure 2a and 2b display the phenotypic traits common to 
oculocutaneous albinism type 4 and neutropenia observed 
in this patient. Figure 2c is a pedigree of the patient’s family, 
both the affected and unaffected individuals. The idiogram 
(graphic chromosome map) in Figure 2d highlights the 
areas of genetic homozygosity. These regions were identi-
fied by single-nucleotide-polymorphism array analysis and 
were considered possible locations for the disease-causing 
mutation(s). Figures 2e and 2f display chromatograms for the 
two disease-causing mutations identified by whole-exome 
sequencing. Figure 2e depicts the mutation in SLC45A2, and 
Figure 2f depicts the mutation in G6PC3. This case portrays 
the valuable role that NGS can play in the correct diagno-
sis of an individual patient who displays disparate symptoms 
with an unidentified genetic cause.
Targeted sequencing
Although whole-genome and whole-exome sequencing are 
possible, in many cases where a suspected disease or con-
dition has been identified, targeted sequencing of specific 
genes or genomic regions is preferred. Targeted sequencing 
is more affordable, yields much higher coverage of genomic 
regions of interest, and reduces sequencing cost and time 
(Xuan et al., 2012). Researchers have begun to develop 
sequencing panels that target hundreds of genomic regions 
that are hotspots for disease-causing mutations. These pan-
els target only desired regions of the genome for sequenc-
ing, eliminating the majority of the genome from analysis. 
Targeted sequencing panels can be developed by researchers 
1.  The basic methodological steps of nGs include  
the following:
A.  Template preparation, emulsion PCR, sequencing, 
data analysis.
B.  Template preparation, sequencing and imaging, 
data analysis.
C.  Template amplification, sequencing and imaging, 
data analysis.
D.  Template preparation, sequencing and imaging, 
alignment to a reference genome.
E.  DNA fragmentation, sequencing, data analysis.
2.  advantages of targeted sequencing as opposed to 
full-genome, exome, or transcriptome sequencing 
include the following:
A.  Affordable and efficient for quickly interrogating 
particular genomic regions of interest.
B.  Provides a deeper coverage of genomic regions 
of interest.
C.  Can be utilized in deciding a therapeutic plan of 
action for both germline and somatic cancers.
D.  Detects and quantifies low-frequency variants 
such as rare drug-resistant viral mutations  
(e.g., HIV, hepatitis B virus, or microbial pathogens).
E.  All of the above.
3.  applications of nGs in medicine include the following:
A.  Detecting mutations that play a role in diseases 
such as cancer.
B.  Identifying genes responsible for inherited skin 
diseases.
C. Determining RNA expression levels.
D.  Identifying novel virulence factors through 
sequencing of bacterial and viral species.
E.  All of the above.
QUESTIONS
Answers are available as supplementary material online  
and at http://www.scilogs.com/jid/.
or clinicians to include specific genomic regions of interest. 
In addition, sequencing panels that target common regions of 
interest can be purchased for clinical use; these include pan-
els that target hotspots for cancer-causing mutations (Rehm, 
2013). Targeted sequencing—whether of individual genes or 
whole panels of genomic regions—aids in the rapid diagno-
sis of many genetic diseases. The results of disease-targeted 
sequencing can aid in therapeutic decision making in many 
diseases, including many cancers for which the treatments 
can be cancer-type specific (Rehm, 2013).
Figure 2. clinical application of whole-exome sequencing in the detection 
of two disease-causing mutations. Reprinted from Cullinane et al., 2011.
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SUPPLEMENTARY MATERIAL
Answers and a PowerPoint slide presentation appropriate for journal club 
or other teaching exercises are available at http://dx.doi.org/10.1038/
jid.2013.248.
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